Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This measurement also informed researchers about the risk of loss of liver function and death in people cured of hepatitis C.
Areas with lower population density have not seen the same slowdown as urban areas.
Almost one in six people with cirrhosis have moderate to severe depression, and close to half have moderate to severe anxiety.
Culturally mindful educational programs may help Black people seek help earlier and throttle hep B incidence rates in these communities.
Women also had a higher rate of hepatocellular carcinoma in the absence of cirrhosis.
No significant links were found between liver stiffness prior to antiviral treatment and cirrhosis, liver cancer or transplants or death.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
October is Liver Cancer Awareness Month.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
NAFLD is the leading indicator of mortality among Medicare beneficiaries with hepatocellular carcinoma.
The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.
The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.